Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.31 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Romifidine SCHEMBL9623631 | 0.98 | PARP10 (0.30) | PARP10PARP11HTT | |
| SCHEMBL4716982 | 0.87 | PARP10 (0.35) | PARP10PARP11 | |
| SCHEMBL11251790 | 0.79 | PARP10 (0.33) | PARP10PARP11 | |
| SCHEMBL11468136 | 0.79 | MAPT (0.32) | PARP10PARP11 | |
| SCHEMBL5157775 | 0.76 | TAAR1 (0.36) | — | |
| Hydrochloric Acid SCHEMBL11613094 | 0.75 | TAAR1 (0.35) | — | |
| SCHEMBL11088921 | 0.69 | LRRK2 (0.41) | HTT | |
| SCHEMBL11559044 | 0.69 | CES2 (0.39) | HTT | |
| SCHEMBL12351496 | 0.69 | HTT (0.40) | HTT | |
| Hydrochloric Acid SCHEMBL11564697 | 0.68 | CES2 (0.38) | HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0178581-B1 | Use of 2-[(2-bromo-6-fluorophenyl)imino]imidazolidine as a sedative | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 1992-01-22 | — | — | EP | claimed |
| US-4624960-A | 2-112-BROMO-6-FLUOROPHENYLIMINOIMIDAZOLIDINE | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 1986-11-25 | — | — | US | claimed |
| EP-0178581-A2 | Use of 2-[(2-bromo-6-fluorophenyl)imino]imidazolidine as a sedative | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 1986-04-23 | — | — | EP | claimed |
| EP-0031429-B1 | 2-(N-(2-FLUORO-6-BROMOPHENYL)-N-(THIEMYL-2-METHYL)-AMINO)-2-IMIDAZOLINE, ITS ADDITION SALTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THEIR PREPARATION | C.H. BOEHRINGER SOHN (DE) | 1984-07-04 | — | — | EP | claimed |
| US-4166859-A | 2-Bromo-6-fluoro-N-(2-imidazolidinylidene)-benzamine and salts thereof and the use to treat hypertension | BOEHRINGER INGELHEIM GMBH (DE) | 1979-09-04 | — | — | US | claimed |
| US-7019021-B2 | Compounds and methods for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-03-28 | — | — | US | disclosed |
| US-6858594-B2 | Compounds and methods for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG. (DE) | 2005-02-22 | — | — | US | disclosed |
| US-20040198796-A1 | Compounds and methods for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-10-07 | — | — | US | disclosed |
| US-20030114425-A1 | Compounds and methods for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-06-19 | — | — | US | disclosed |
| EP-1285653-A1 | Use of alpha-1L agonists in the treatment of incontinence | Boehringer Ingelheim Pharma KG (DE) | 2003-02-26 | — | — | EP | disclosed |
| US-6268389-B1 | Treatment of urinary incontinence by administration of α1L-adrenoceptor agonists | BOEHRINGER INGELHEIM KG (DE) | 2001-07-31 | — | — | US | disclosed |
| EP-0497240-B1 | Preparation for controlled release of drugs for ruminants | HOECHST AG (DE) | 1998-04-08 | — | — | EP | disclosed |
| US-4624960-A | 2-112-BROMO-6-FLUOROPHENYLIMINOIMIDAZOLIDINE | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 1986-11-25 | — | — | US | disclosed |
| EP-0178581-A2 | Use of 2-[(2-bromo-6-fluorophenyl)imino]imidazolidine as a sedative | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 1986-04-23 | — | — | EP | disclosed |
| EP-0178581-A2 | Use of 2-[(2-bromo-6-fluorophenyl)imino]imidazolidine as a sedative | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 1986-04-23 | — | — | EP | disclosed |
| US-4478844-A | Bradycardiac or analgesic 2-(N-(thienyl-2-methyl)-N-(2-fluoro-6-methyl-phenyl)-amino)-2-imidazoline and salts thereof | BOEHRINGER INGELHEIM KG (DE) | 1984-10-23 | — | — | US | disclosed |
| EP-0031429-B1 | 2-(N-(2-FLUORO-6-BROMOPHENYL)-N-(THIEMYL-2-METHYL)-AMINO)-2-IMIDAZOLINE, ITS ADDITION SALTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THEIR PREPARATION | C.H. BOEHRINGER SOHN (DE) | 1984-07-04 | — | — | EP | disclosed |
| EP-0031429-A1 | 2-(N-(2-Fluoro-6-bromophenyl)-N-(thiemyl-2-methyl)-amino)-2-imidazoline, its addition salts, pharmaceutical compositions containing them and processes for their preparation | C.H. BOEHRINGER SOHN (DE) | 1981-07-08 | — | — | EP | disclosed |
| US-4166859-A | 2-Bromo-6-fluoro-N-(2-imidazolidinylidene)-benzamine and salts thereof and the use to treat hypertension | BOEHRINGER INGELHEIM GMBH (DE) | 1979-09-04 | — | — | US | disclosed |
| US-4166859-A | 2-Bromo-6-fluoro-N-(2-imidazolidinylidene)-benzamine and salts thereof and the use to treat hypertension | BOEHRINGER INGELHEIM GMBH (DE) | 1979-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114425-A1 | Compounds and methods for treating urinary incontinence | PDE3A, PDE3B, PDE2A | PARP10 3390/4885PARP11 3143/4885HTT 3766/4885 |
| US-20040198796-A1 | Compounds and methods for treating urinary incontinence | REN, ARG1, RXFP1 | PARP10 3436/4885PARP11 2553/4885HTT 3930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.